From raw data in the laboratory to information availability in the enterprise By Dieter Kreusel If pharmaceutical or biotechnology companies could measure their success merely on the volume of raw data accumulated from screening assays and pre-clinical testing, they would be basking in the glow of unprecedented success. Companies are… Read More
Cell Based Assays - Seeing the light By Dr Nick Thomas High-context cell assays have the potential to take the pivotal role in the drug discovery process. So what are the features of today's leading edge cell based assay technologies and where does the future lie? We live in interesting… Read More
Hit to lead and lead to candidate optimisation using multi-parametric principles By Dr Anthony D. Baxter and Dr Peter M. Lockey As the numbers of potential target proteins become available for pharmaceutical companies of all sizes, the drive towards more cost-effective drug discovery assumes greater significance. It is a truism… Read More
Unrealised wealth in the avalanche of science By Dr Benjamin P. Chen The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora's box of intellectual properties opened as a result is beyond… Read More
Biologically Relevant Chemistry By Dr Stephen A. Hill A large proportion of R&D expenditure relates to the investigation of compounds which ultimately fail to reach the market as useful medicines. We discuss why early drug discovery - using high throughput, automated in vitro and in silico methods, must become the… Read More
Pharmaceutical Industry R&D Partnering Strategies By Riccardo Pigliucci Drug Discovery With a sustained rate of more than 250 R&D partnering deals each year many valuable lessons are being learned. Although there is no exact 'formula for success' there are many 'success factors' that can be utilised to reduce the risk… Read More
Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury For HTS laboratories worldwide, the mission is to supply therapeutic groups in the shortest time possible with high quality hits and leads that will become drug candidates. Mounting pressure to… Read More
HTS a strategy for drug discovery By Dr AR Knight, Cerebrus Ltd Whichever technologies are implemented, high throughput screening is set to become one of the cornerstones of drug discovery, however deciding which strategy to implement will provide many headaches. This article concentrates on screens identifying the interaction of small… Read More